Aurealis Therapeutics is a Swiss-Nordic Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammation. After successfully completing our Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients with our lead clinical product AUP-16, we are initiating our Phase 2 study in Italy, Germany and Poland, first for DFU. Venous Ulcers and Pressure Ulcers will follow. In Oncology, we are building on impressive pre-clinical data with Oncolytic Bacteria lead candidate AUP-55, which shows increased survival in Ovarian Cancer and peritoneal carcinomatosis. Our pipeline also includes Inflammation, at discovery stage.
Location: Finland, Mainland Finland, Kuopio
Employees: 11-50
Total raised: $9.07M
Founded date: 2015
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.11.2024 | - | $9.07M | - |
Mentions in press and media 15
| Date | Title | Description |
| 15.11.2024 | Aurealis Therapeutics raises CHF8 million | Aurealis’ cell and gene therapies allow to modulate tissue microenvironment and tackle complex multi-factorial diseases such as chronic wounds, cancers, and inflammation. Aurealis modular gene therapy platform consists of non-pathogenic la... |
| 06.11.2024 | Biotech companies report progress in clinical trials | Following the sale of its lead molecule NM26 to Johnson & Johnson for USD 1.25 billion in May, Numab Therapeutics announced the start of a Phase 1 clinical trial evaluating NM32, a next generation tri-specific immuno-oncology therapeut... |
| 11.03.2024 | Aurealis Therapeutics completes 50% patient recruitment for DIAMEND Phase-2 study in Diabetic Foot Ulcers | Aurealis Therapeutics AUP-16 4-in-1 Bacterial Vector for Chronic Wounds Half of the patients expected to participate DIAMEND Phase-2 study with AUP-16 in Diabetic Foot Ulcers (DFUs) have now been recruited and randomized. ZUG, SWITZERLAND, ... |
| 27.02.2024 | Aurealis Therapeutics’ lead candidate AUP-16 for chronic wounds receives PRIME status from EMA | AUP-16 multi-target cell & gene therapy for Chronic Wounds Aurealis Therapeutics receives PRIME status from EMA for Enhanced Regulatory Support and Accelerated Assessment of AUP-16 in Non-healing Diabetic Foot Ulcers ZUG, SWITZERLAND, F... |
| 08.08.2023 | Aurealis Therapeutics Announces First Patient Dosed in DIAMEND Phase 2 Diabetic Foot Ulcer Clinical Trial of AUP-16 | Aurealis Therapeutics AUP-16 4-in-1 Bacterial Vector for Chronic Wounds BASEL, BASEL-STADT, SWITZERLAND, August 8, 2023/EINPresswire.com/ -- Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria... |
| 05.06.2023 | A significant number of Swiss biotechs exhibit in Boston | |
| 10.05.2023 | Biotech startups turn gear into Phase 2 clinical trials | |
| 09.05.2023 | Aurealis Therapeutics receives CTA approval for AUP-16 Phase 2 RCT in Diabetic Foot Ulcer patients | Aurealis Therapeutics AUP-16 4-in-1 Bacterial Vector for Chronic Wounds Multi-center, randomized, placebo-controlled diabetic foot ulcer (DFU) Phase 2 study to start May 2023 in Italy, Germany, and Poland After completing 12 months follow-u... |
| 04.04.2023 | Aurealis Therapeutics banks $10 million in an oversubscribed round | |
| 31.01.2022 | Aurealis to receive up to $139 million in collaboration agreement |
Show more